Published: September 2004
Pages: 48
Published by: HTStec

Table of Contents

This market report summarizes the results of a comprehensive global Pharma web-based survey on GPCR assay trends. In particular, it examines through documentation of screening metrics and budgets the relative importance of GPCR primary screening and selectivity profiling both in house and outsourced, the preferences of respondents for assay detection technologies, suppliers/products and fee-for-service providers.

Highlights of this Report:

• The survey collected 63 responses (52 complete and 11 partially filled out) from 48 different Pharma/Biotech companies.
• Responses were split geographically 43% North America and 57% Europe.
• Survey respondents were drawn from 27 Large Pharma, 33 Small Pharma/Biotechs, 1 Large Agro Company, Baby and Clinical Nutrition Company and 1 Pharma-Linked Research Organization.
• Survey respondents represented 27 primary screening (HTS) labs, 15 assay development labs, 12 secondary screening/hits-toleads (lead optimization) labs, 2 therapeutic area labs, 1 compound profiling lab and 6 other lab functions.
• Survey results were expressed as an industry average of all respondents. In addition, all results were fully reanalyzed after subdivision into the following survey groups: 1) by organization type - Large Pharma; 2) by organization type - Small Pharma/Biotech; 3) by geographic location - North America and 4) by geographic location – Europe.
• The mean number of primary GPCR screens undertaken in 2004 was estimated to be 7.1 screens per year with 489K wells (data points) per screen.
• Globally it was estimated that 1533 GPCR primary screens campaigns will be performed in 2004, 71% will be cell-based and 6% orphans.
• The Pharma market for GPCR primary screening reagents was estimated to be US$70Million in 2004, with an annual growth rate of 26%.
• The preferred approaches to GPCR profiling were to either to screen selected lead compounds in house against a GPCR panel or to outsource screening of selected lead compounds to a fee-for-service GPCR panel provider.
• The Pharma market for GPCR profiling was estimated in 2004 to be US$37.6Million and US$36.2Million for in house and outsourced profiling respectively.
• About 8X more data points were profiled against GPCRs in house versus outsourced in 2004.
• The mean budget allocated per lab for GPCR profiling in 2004 was estimated to be US$175K in house versus US$168K for outsourced profiling.
• The mean price per data point for GPCR profiling was estimated to be US$4.30 in house versus US$35.42 for outsourced.
• The mean number of FTEs supporting in house GPCR screening and profiling was 5.4 and 2.8 FTEs/lab respectively.

Purchase report >>